Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
AFC-HD AMS Life Science, First Half Ordinary Profit Increases by 26%, Dec-Feb Ordinary Profit Increases by 10%
2927 AFC-HD AMS Life Science Co.,Ltd. 【J-GAAP】
Earnings ReportAFC-HD AMS Life Science Co.,Ltd. <2927> [TSE Std] announced its financial results after the market closed on April 14th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending August 2025 (September 2024 to February 2025) increased 25.7% from the same period last year, reaching 1.33 billion yen. The progress rate toward the full-year plan of 2.2 billion yen was 60.5%, also surpassing the five-year average of 49.0%.
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the March to August period (2H) is expected to nearly flat at 0.86 billion yen, up 0.8% from the same period last year.
In the most recent three-month period, from December to February (2Q), the consolidated ordinary profit grew 10.0% from the same period last year, reaching 0.62 billion yen. The operating profit margin improved from 7.0% in the same period last year to 7.6%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Sep - Feb, 2022 | 12,444 | 678 | 708 | 414 | 29.5 | 42.8 | Apr 14, 2023 | J-GAAP |
Sep - Feb, 2023 | 14,542 | 1,023 | 1,060 | 641 | 45.8 | 55.2 | Apr 15, 2024 | J-GAAP |
Sep - Feb, 2024 | 16,614 | 1,294 | 1,332 | 881 | 62.7 | 60.5 | Apr 14, 2025 | J-GAAP |
YoY | +14.2% | +26.5% | +25.7% | +37.4% | +36.8% |
First Half Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Sep - Feb, 2024 Guidance | 16,690 | 1,329 | 1,366 | 904 | 64.3 | 16 | Apr 3, 2025 | J-GAAP |
Sep - Feb, 2024 Results | 16,614 | 1,294 | 1,332 | 881 | 62.7 | 16 | Apr 14, 2025 | J-GAAP |
Revision Rate | -0.5% | -2.6% | -2.5% | -2.5% | -2.6% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar - Aug, 2024 | 15,643 | 893 | 861 | 611 | 43.5 | 15 | Oct 15, 2024 | J-GAAP |
Mar - Aug, 2025 Guidance | 14,486 | 906 | 868 | 439 | 31.2 | 16 | Apr 14, 2025 | J-GAAP |
YoY | -7.4% | +1.5% | +0.8% | -28.2% | -28.3% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Aug, 2023 | 25,579 | 1,636 | 1,654 | 1,102 | 78.5 | 27.50 | Oct 13, 2023 | J-GAAP |
Aug, 2024 | 30,185 | 1,916 | 1,921 | 1,252 | 89.2 | 30 | Oct 15, 2024 | J-GAAP |
Aug, 2025 Guidance | 31,100 | 2,200 | 2,200 | 1,320 | 93.9 | 32 | Oct 15, 2024 | J-GAAP |
YoY | +3.0% | +14.8% | +14.5% | +5.4% | +5.3% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 7,756 | 545 | 571 | 323 | 23.1 | 7.0 | Apr 15, 2024 | J-GAAP |
Mar - May, 2024 | 7,802 | 472 | 454 | 281 | 20.1 | 6.0 | Jul 16, 2024 | J-GAAP |
Jun - Aug, 2024 | 7,841 | 421 | 407 | 330 | 23.5 | 5.4 | Oct 15, 2024 | J-GAAP |
Sep - Nov, 2024 | 8,189 | 650 | 704 | 460 | 32.7 | 7.9 | Jan 14, 2025 | J-GAAP |
Dec - Feb, 2024 | 8,425 | 644 | 628 | 421 | 29.9 | 7.6 | Apr 14, 2025 | J-GAAP |
YoY | +8.6% | +18.2% | +10.0% | +30.3% | +29.8% |
Related Articles
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%
Maruto Sangyo, 15% Increase in Ordinary Profit for The Current Fiscal Year
VALUE CREATION, 50% Increase in Ordinary Profit, Record High for The First Time in Two Years, Dividend Raised by 0.5 yen
Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%
KAWAKAMI PAINT, Dec-Feb (1Q) Ordinary Profit Turns to Loss
Life Foods, 52% Decrease in Ordinary Profit for The Current Fiscal Year, Resuming Dividends at 5 yen for the First Time in five terms., Plan to Continue the 5 yen Policy This Fiscal Year as Well
KAITORI OKOKU, 17% Increase in Ordinary Profit, Record High for The First Time in Two Years
TOKYO KOKI, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 4.7 times Increase in Ordinary Profit for The Current Fiscal Year
TONE, Jun-Feb (Cumulative 3Q) Ordinary Profit Increases by 22%
Takashimaya, 1% Increase in Ordinary Profit, Update Record High for Third Consecutive Term, Increased Previous Year's Dividend by 1.5 yen, This Fiscal Year to Increase Dividend